BELITE BIO, INC (BLTE) Cash Flow Statement
BELITE BIO, INC (BLTE) generated -$37.0M of operating cash flow over the twelve months to its latest filing, spent $178000 on capital expenditure and had free cash flow of -$37.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
BLTEBELITE BIO, INCFollow BLTE — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.5 | -29.8 | -29.2 | -37.0 | -37.0 | |
| Capital expenditure | 0.4 | 0.1 | 0.1 | 0.2 | -0.2 | |
| Free cash flow | -11.9 | -29.9 | -29.4 | -37.2 | -37.2 | |
| Stock-based compensation | 1.5 | 3.8 | 9.0 | 38.9 | — |
USD millions · SEC XBRL
BELITE BIO, INC — questions
- What is BELITE BIO, INC's operating cash flow?
- -$37.0M over the twelve months to the latest filing.
- How much does BELITE BIO, INC spend on capital expenditure?
- $178000 over the twelve months to the latest filing.
- What is BELITE BIO, INC's free cash flow?
- -$37.2M over the twelve months to the latest filing: operating cash flow minus capital expenditure.
Every figure on this page comes from BELITE BIO, INC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.